The Urology-Oncology Partnership in ADCs
About this episode
This episode discusses the integration of antibody-drug conjugates in the treatment of bladder cancer and the importance of collaboration between urology and medical oncology.
In 2025, the FDA approved the antibody-drug conjugate (ADC) enfortumab vedotin combined with pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer, unlocking a new perioperative treatment option. To administer this ADC-based therapy alongside surgical intervention, multidisciplinary teams must prioritize collaborative workflows at all points of the treatment journey. In this episode, CANCER BUZZ speaks with Manojkumar Bupathi, MD, President of Rocky Mountain Cancer Centers, about how ADCs are reshaping the care model toward earlier, structured collaboration between urology and medical oncology. Guests: Manojkumar Bupathi, MD President Rocky Mountain Cancer Centers Co-Chair, GU Executive Committee Sarah Cannon Research Institute Denver, CO "The challenge wasn't learning the drug itself. The challenge was how you integrate the regimen into your treatment paradigm." —Manojkumar Bupathi, MD "There's always this relationship that happens from the beginning and is maintained throughout the entire process." —Manojkumar Bupathi, MD Resources: ACCC Bladder Cancer Resources ACCC Antibody-Drug Conjugate Resources
More episodes of CANCER BUZZ
- A Team Approach to ADCs in Bladder Cancer
- MDS: Low Risk Isn't No Risk
- Beyond Body Art: Restoring Wholeness Through Paramedical Tattooing
- Bridging Radiation and Oncology in SCLC Care
- Championing Bispecific Antibodies in the VA
- Data-Driven Toxicity Management for ADCs
Explore listener stats, chart rankings, contacts and more on the CANCER BUZZ podcast page.